Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: A potential therapeutic target

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 509-515

  Su, Jang Ming ^a   Lin, Pinpin ^b   Wang, Chien Kai ^b   Chang, Han ^c,d  

^a KUANG TIEN GENERAL HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Aryl hydrocarbon receptor; CYP1B1; Epidermal growth factor receptor; Lung cancer; p53

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BIOLOGICAL MARKER; CYTOCHROME P450 1B1; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TISSUE MICROARRAY;

ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ARYL HYDROCARBON; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 61449200566     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Devesa SS, Bray F, Vizcaino AP and Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117: 294-299, 2005.
2. Rowlands JC and Gustafsson JA: Aryl hydrocarbon receptor-mediated signal transduction. Crit Rev Toxicol 27: 109-134, 1997.
3. Shehin SE, Stephenson RO and Greenlee WF: Transcriptional regulation of the human CYP1B1 gene. Evidence for involvement of an aryl hydrocarbon receptor response element in constitutive expression. J Biol Chem 275: 6770-6776, 2000.
4. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP and Sutler TR: Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 56: 2979-2984, 1996.
5. Chang JT, Chang H, Chen PH, Lin SL and Lin P: Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 upregulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 13: 38-45, 2007.
6. Lin P, Chang H, Ho WL, Wu MH and Su JM: Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human non-small cell lung cancers. Lung Cancer 42: 255-261, 2003.
7. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR and Tsai SF: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203, 2004.
8. Scagliotti GV, Selvaggi G, Novelle S and Hirsch FR: The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 10: 4227s-4232s, 2004.
9. Partanen AM, Alaluusua S, Miettinen PJ, Thesleff I, Tuomisto J, Pohjanvirta R and Lukinmaa PL: Epidermal growth factor receptor as a mediator of developmental toxicity of dioxin in mouse embryonic teeth. Lab Invest 78: 1473-1481, 1998.
10. Abbott BD, Buckalew AR, De Vito MJ, Ross D, Bryant PL and Schmid JE: EGF and TGF-alpha expression influence the developmental toxicity of TCDD: dose response and AhR phenotype in EGF, TGF-alpha, and EGF + TGF-alpha knockout mice. Toxicol Sci 71: 84-95, 2003.
11. Randi AS, Sanchez MS, Alvarez L, Cardozo J, Pontillo C and de Pisarev DL: Hexachlorobenzene triggers AhR translocation to the nucleus, c-Src activation and EGFR transactivation in rat liver. Toxicol Lett 177: 116-122, 2008.
12. Sidransky D and Hollstein M: Clinical implications of the p53 gene. Annu Rev Med 47: 285-301, 1996.
13. Ko CB, Kim SJ, Park C, Kim BR, Shin CH, Choi S, Chung SY, Noh JH, Jeun JH, Kim NS and Park R: Benzo(a)pyrene-induced apoptotic death of mouse hepatoma Hepalclc? cells via activation of intrinsic caspase cascade and mitochondrial dysfunction. Toxicology 199: 35-46, 2004.
14. Solhaug A, Refsnes M. Lag M, Schwarze PE, Husoy T and Holme JA: Polycyclic aromatic hydrocarbons induce both apoptotic and anti-apoptotic signals in Hepa1c1c7 cells. Carcinogenesis 25: 809-819, 2004.
15. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M, eds: AJCC Cancer Staging Manual. New York, Springer-Verlag, pp. 167-177, 2002.
16. Lin P, Chang H, Tsai WT, Wu MH, Liao YS, Chen JT and Su JM: Overexpression of aryl hydrocarbon receptor in human lung carcinomas. Toxicol Pathol 31: 22-30, 2003.
17. Ries LA: Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol 10: 21-30, 1994.
18. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S and Murray GI: Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res 11: 3758-3765, 2005.
19. Schneider Y, Vincent F, Duranton B, Badolo L, Gosse F, Bergmann C, Seiler N and Raul F: Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonie cancer cells. Cancer Lett 158: 85-91, 2000.
20. Lu J, Ho CH, Ghai G and Chen KY: Resveratrol analog, 3,4,5,4′- tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis 22: 321-328, 2001.
21. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH et al: The cancer preventive agent resveratrol is converted to the anticancer agent piceatannol by cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778, 2002.
22. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D and Nadler LM: Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11: 4430-4436, 2005.
23. Spink BC, Hussain MM, Katz BH, Eisele L and Spink DC: Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells by indirubin. Biochem Pharmacol 66: 2313-2321, 2003.
24. Zheng W, Brake PB, Bhattacharyya KK, Zhang L, Zhao D and Jefcoate CR: Cell selective cAMP induction of rat CYP1B1 in adrenal and testis cells. Identification of a novel cAMP-responsive far upstream enhancer and a second Ah receptor-dependent mechanism. Arch Biochem Biophys 416: 53-67, 2003.
25. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, Ogishima T, Okino ST, Li LC, Tanaka Y, Nonomura N, Okuyama A and Dahiya R: Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res 11: 5793-5801, 2005.
26. Pavelic K, Banjac Z, Pavelic J and Spaventi S: Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13: 1133-1137, 1993.
27. Xue C, Wyckoff J, Liang F, Sidani M, Violini S, Tsai KL, Zhang ZY, Sahai E, Condeelis J and Segall JE: Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 66: 192-197, 2006.
28. Hung MS, Lin CK, Leu SW, Wu MY, Tsai YH and Yang CT: Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. Chang Gung Med J 29: 373-379, 2006.
29. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
30. Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, Minna JD, Gazdar AF and Fujisawa T: Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36: 1127-1134, 2005.
31. Choi SS, Miller MA and Harper PA: In utero exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin induces amphiregulin gene expression in the developing mouse ureter. Toxicol Sci 94: 163-174, 2006.
32. Wu R, Zhang L, Hoagland MS and Swanson HI: Lack of the aryl hydrocarbon receptor leads to impaired activation of AKT/protein kinase B and enhanced sensitivity to apoptosis induced via the intrinsic pathway. J Pharmacol Exp Ther 320: 448-457, 2007.
33. Schrenk D, Schmitz HJ, Bohnenberger S, Wagner B and Worner W: Tumor promoters as inhibitors of apoptosis in rat hepatocytes. Toxicol Lett 149: 43-50, 2004.
34. Hoagland MS, Hoagland EM and Swanson HI: The p53 inhibitor pifithrin-alpha is a potent agonist of the aryl hydrocarbon receptor. J Pharmacol Exp Ther 314: 603-610, 2005.